Novavax Inc's COVID-19 vaccine NVX-CoV2373 demonstrated 90.4% overall efficacy against SARS-CoV-2 infection, and 100% protection against moderate and severe disease, according to a Phase 3 PREVENT-19 clinical trial.
The FDA approved sotorasib (Lumakras, Amgen Inc) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C.
A five-year trial found at least 75% of Fasenra-treated asthma patients with elevated blood eosinophil levels had zero exacerbations each year of the open-label period.
A Phase I/II clinical trial in the Netherlands will test AKS-452, a COVID-19 vaccine candidate that is shelf-stable for at least 4 months without refrigeration.
The US FDA has expanded the approval of Ragwitek for sublingual use to treat short ragweed pollen-induced allergic rhinitis in patients aged five through 17.
The European Medicines Agency’s CHMP adopted a positive opinion for a label extension of Kaftrio (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor for certain cystic fibrosis patients.